Opinion|Videos|January 31, 2025
Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes
Author(s)Hadar Lev-Tov, MD
Panelist discusses how patient advocacy groups act as critical bridges between patients, researchers, and health care providers, ultimately improving recognition, treatment, and quality of life for individuals affected by hidradenitis suppurativa.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you discuss the role of patient advocacy groups in promoting early recognition and comprehensive care for HS?
- Closing thoughts on HS for the AJMC viewing audience.
Advertisement
Related to this article
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
3
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
4
FDA Expands Mavacamten Label to Include Children With oHCM
5